A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients

Journal of Mass Spectrometry

Volumn 48, Issue 5, 2013, Pages 616-625

  Aouri, Manel ^a   Calmy, Alexandra ^b   Hirschel, Bernard ^b   Telenti, Amalio ^a   Buclin, Thierry ^a   Cavassini, Matthias ^a   Rauch, Andri ^c   Decosterd, Laurent A ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

analytical methods validation; anti HIV therapy; elvitegravir; rilpivirine; stable labeled isotopes; tandem mass spectrometry; therapeutic drug monitoring

Indexed keywords

ANALYTICAL METHOD; ANTI-HIV; ELVITEGRAVIR; RILPIVIRINE; TANDEM MASS SPECTROMETRY; THERAPEUTIC DRUG MONITORING;

CALIBRATION; DRUG THERAPY; ELECTROSPRAY IONIZATION; EXTRACTION; ISOTOPES; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PATIENT MONITORING; PHARMACOKINETICS; PLASMAS;

PLASMA STABILITY;

ACETONITRILE; AMMONIUM ACETATE; ELVITEGRAVIR; GLUCURONIDE; RILPIVIRINE;

ARTICLE; CALIBRATION; CONTROLLED STUDY; DRUG MONITORING; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETER; PLASMA; PRECIPITATION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; REVERSED PHASE LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY; VALIDATION STUDY; VIRUS INACTIVATION;

ANTI-RETROVIRAL AGENTS; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; HIV INFECTIONS; HUMANS; NITRILES; PYRIMIDINES; QUINOLONES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84877828566     PISSN: 10765174     EISSN: 10969888     Source Type: Journal    
DOI: 10.1002/jms.3200     Document Type: Article

References (38)

1. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the Use of Antiretroviral Agents in Hiv-1-Infected Adults and Adolescents. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
2. R. K. Ghosh, S. M. Ghosh, S. Chawla,. Recent advances in antiretroviral drugs. Expert Opin. Pharmacother. 2011, 12, 31-46.
3. N. Prada, M. Markowitz,. Novel integrase inhibitors for HIV. Expert Opin. Investig. Drugs 2010, 19, 1087-98.
4. Edurant (Rilpivirine). (http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Summary-for-the-public/human/002264/WC500118873.pdf
5. Fda Label for Edurant™ (rilpivirine) Tablets. http://www. accessdata.fda.gov/drugsatfda-docs/label/2011/202022s000lbl.pdf
6. C. J. Cohen, J. Andrade-Villanueva, B. Clotet, J. Fourie, M. A. Johnson, K. Ruxrungtham, H. Wu, C. Zorrilla, H. Crauwels, L. T. Rimsky, S. Vanveggel, K. Boven,. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (Thrive): a phase 3, randomised, non-inferiority trial. Lancet 2011, 378, 229-37.
7. J. M. Molina, P. Cahn, B. Grinsztejn, A. Lazzarin, A. Mills, M. Saag, K. Supparatpinyo, S. Walmsley, H. Crauwels, L. T. Rimsky, S. Vanveggel, K. Boven,. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (Echo): a phase 3 randomised double-blind active-controlled trial. Lancet 2011, 378, 238-46.
8. E. DeJesus, D. Berger, M. Markowitz, C. Cohen, T. Hawkins, P. Ruane, R. Elion, C. Farthing, L. Zhong, A. K. Cheng, D. McColl, B. P. Kearney,. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor Gs-9137 (Jtk-303) in treatment-naive and treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 2006, 43, 1-5.
9. B. A. Desimmie, R. Schrijvers, Z. Debyser,. Elvitegravir: a once daily alternative to raltegravir. Lancet Infect. Dis. 2012, 12, 3-5.
10. J. M. Molina, A. Lamarca, J. Andrade-Villanueva, B. Clotet, N. Clumeck, Y. P. Liu, L. Zhong, N. Margot, A. K. Cheng, S. L. Chuck, Team Study. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect. Dis. 2012, 12, 27-35.
11. M. Metifiot, N. Vandegraaff, K. Maddali, A. Naumova, X. Zhang, D. Rhodes, C. Marchand, Y. Pommier,. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS 2011, 25, 1175-8.
12. S. Ramanathan, A. A. Mathias, P. German, B. P. Kearney,. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin. Pharmacokinet. 2011, 50, 229-44.
13. Fda Label for Complera™. http://www.accessdata.fda.gov/drugsatfda- docs/label/2011/202123s000lbl.pdf.
14. K. C. Brown, S. Paul, A. D. Kashuba,. Drug interactions with new and investigational antiretrovirals. Clin. Pharmacokinet. 2009, 48, 211-41.
15. C. Cohen, R. Elion, P. Ruane, D. Shamblaw, E. DeJesus, B. Rashbaum, S. L. Chuck, K. Yale, H. C. Liu, D. R. Warren, S. Ramanathan, B. P. Kearney,. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011, 25, F7-12.
16. L. Dickinson, S. Khoo, D. Back,. Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. Antiviral Res. 2010, 85, 176-89.
17. A. Buelens, S. Vanveggel, H. M. Crauwels, R. P. G. van Heeswijk, L. Leopold, M. Stevens, K. Boven,. TMC278 25 Mg Qd has no effect on corrected Qt interval in a study in HIV-negative volunteers. in presented at the 12th European AIDS Conference Cologne, Germany, 2009.
18. G. van 't Klooster, E. Hoeben, H. Borghys, A. Looszova, M. P. Bouche, F. van Velsen, L. Baert,. Pharmacokinetics and disposition of rilpivirine (Tmc278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob. Agents Chemother. 2010, 54, 2042-50.
19. E. Van Gyseghem, M. Pendela, L. Baert, J. Rosier, G. Van 't Klooster, H. De Man, M. P. Bouche, L. Schueller, P. Van Remoortere, P. Wigerinck, E. Adams, J. Hoogmartens, G. Van den Mooter,. Powder for reconstitution of the anti-HIV-1 drug Tmc278-formulation development, stability and animal studies. Eur. J. Pharm. Biopharm. 2008, 70, 853-60.
20. L. Burugula, N. R. Pilli, A. Makula, D. S. Lodagala, R. Kandhagatla,. Liquid chromatography-tandem mass spectrometric assay for the non-nucleoside reverse transcriptase inhibitor rilpivirine in human plasma. Biomed. Chromatogr. 2013, 27, 172-8.
21. L. Else, V. Watson, J. Tjia, A. Hughes, M. Siccardi, S. Khoo, D. Back,. Validation of a rapid and sensitive high-performance liquid chromatography- tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2010, 878, 1455-65.
22. S. Ramanathan, G. Shen, A. Cheng, B. P. Kearney,. Pharmacokinetics of emtricitabine, tenofovir, and Gs-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted Gs-9137. J. Acquir. Immune Defic. Syndr. 2007, 45, 274-9.
23. FDA. Homepage, guidance for industry: bioanalytical method validation. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM070107.pdf.
24. C. H. Koks, H. Rosing, P. L. Meenhorst, A. Bult, J. H. Beijnen,. High-performance liquid chromatographic determination of the antifungal drug fluconazole in plasma and saliva of human immunodeficiency virus-infected patients. J. Chromatogr. B Biomed. Appl. 1995, 663, 345-51.
25. J. S. McDougal, L. S. Martin, S. P. Cort, M. Mozen, C. M. Heldebrant, B. L. Evatt,. Thermal inactivation of the acquired immunodeficiency syndrome virus, human t lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor. J. Clin. Invest. 1985, 76, 875-7.
26. G. V. Quinnan, Jr., M. A. Wells, A. E. Wittek, M. A. Phelan, R. E. Mayner, S. Feinstone, R. H. Purcell, J. S. Epstein,. Inactivation of human T-cell lymphotropic virus, type III by heat, chemicals, and irradiation. Transfusion 1986, 26, 481-3.
27. C. T. Viswanathan, S. Bansal, B. Booth, A. J. DeStefano, M. J. Rose, J. Sailstad, V. P. Shah, J. P. Skelly, P. G. Swann, R. Weiner,. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 2007, 24, 1962-73.
28. V. P. Shah, K. K. Midha, J. W. Findlay, H. M. Hill, J. D. Hulse, I. J. McGilveray, G. McKay, K. J. Miller, R. N. Patnaik, M. L. Powell, A. Tonelli, C. T. Viswanathan, A. Yacobi,. Bioanalytical method validation-a revisit with a decade of progress. Pharm. Res. 2000, 17, 1551-7.
29. B. K. Matuszewski,. Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2006, 830, 293-300.
30. B. K. Matuszewski, M. L. Constanzer, C. M. Chavez-Eng,. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75, 3019-30.
31. M. Aouri, L. A. Decosterd, T. Buclin, B. Hirschel, A. Calmy, F. Livio,. Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with aspergillus pneumonia. AIDS 2012, 26, 776-8.
32. H. R. Liang, R. L. Foltz, M. Meng, P. Bennett,. Ionization enhancement in atmospheric pressure chemical ionization and suppression in electrospray ionization between target drugs and stable-isotope-labeled internal standards in quantitative liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2003, 17, 2815-21.
33. L. E. Sojo, G. Lum, P. Chee,. Internal standard signal suppression by co-eluting analyte in isotope dilution LC-ESI-MS. Analyst 2003, 128, 51-4.
34. A. Haouala, B. Zanolari, B. Rochat, M. Montemurro, K. Zaman, M. A. Duchosal, H. B. Ris, S. Leyvraz, N. Widmer, L. A. Decosterd,. Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877, 1982-96.
35. J. F. Jourdil, M. Bartoli, F. Stanke-Labesque,. Lack of specificity for the analysis of raltegravir using online sample clean-up liquid chromatography-electrospray tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877, 3734-8.
36. N. A. Margot, R. M. Hluhanich, G. S. Jones, K. N. Andreatta, M. Tsiang, D. J. McColl, K. L. White, M. D. Miller,. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antiviral Res. 2012, 93, 288-96.
37. European Medicines Agency. Assessment report edurant, 2011.
38. D. Zhang, T. J. Chando, D. W. Everett, C. J. Patten, S. S. Dehal, W. G. Humphreys,. In vitro inhibition of udp glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab. Dispos. 2005, 33, 1729-39.